Seeking Alpha assigned Tempus AI a "Strong Buy" rating. The report argues the company transforms into a dominant healthcare data provider.
The analysis highlights rapid scaling of Tempus AI's high-margin data and applications business. It also notes explosive growth in its diagnostics segment.
Tempus AI's first-quarter 2026 results support this thesis. Data segment revenue increased 40.5% year-over-year. Revenue reached $87 million.
The report also emphasized a 500% surge in Molecular Residual Disease (MRD) testing volume. This volume contributes valuable data for pharmaceutical clients.
The analyst projects the data services segment could reach $950 million in revenues by 2029. This forms the core of the bullish valuation.